J&J | JNJ - Cost Of Sales


J&J reported $8B in Cost of Sales for its fiscal quarter ending in June of 2026.





Cost Of Sales Change Date
AbbVie USD 4.22B 329M Mar/2026
Abbott USD 5.94B 642M Jun/2026
Amgen USD 1.6B 187M Mar/2026
AstraZeneca USD -204M 3.48B Mar/2026
Baxter International USD 1.81B 587M Mar/2026
Bayer EUR 5.23B 731M Mar/2026
Becton, Dickinson and Co. USD 2.56B 281M Mar/2026
Biogen USD 797.5M 302M Mar/2026
Boston Scientific USD 1.83B 8M Mar/2026
Bristol-Myers Squibb USD 3.86B 1.07B Mar/2026
CONMED USD 133.6M 21.31M Mar/2026
Cooper Companies USD 393.8M 17M Mar/2026
Dexcom USD 441.6M 25.3M Mar/2026
Edwards Lifesciences USD 362.6M 19.6M Mar/2026
Eli Lilly USD 3.58B 205M Mar/2026
Gilead Sciences USD 1.44B 174M Mar/2026
GlaxoSmithKline GBP 1.88B 736M Mar/2026
Globus Medical USD 263.59M 26.88M Mar/2026
Insulet USD 232.7M 17.5M Mar/2026
Integra LifeSciences USD 178.71M 14.73M Mar/2026
Intuitive Surgical USD 931.9M 8.4M Jun/2026
J&J USD 8B 67M Jun/2026
Medtronic USD 3.8B 195M Mar/2026
Merck USD 2.94B 380M Mar/2026
Merit Medical Systems USD 197.08M 1.5M Mar/2026
Novartis USD 3.46B 83M Mar/2026
Pfizer USD 4.59B 1.7B Mar/2026
Regeneron Pharmaceuticals USD 669.4M 84.8M Mar/2026
Roche Holding CHF 8.48B 4.61B Dec/2025
Sanofi EUR 3.67B 621M Mar/2026
Stryker USD 2.36B 325M Mar/2026
Tandem Diabetes Care USD 122.92M 7.96M Dec/2025
Teva Pharmaceutical Industries USD 2.01B 46M Mar/2026
Vertex Pharmaceuticals USD 392.8M 73.2M Mar/2026
Zimmer Biomet Holdings USD 738.3M 231.8M Mar/2026
Zoetis USD 672M 71M Mar/2026